Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zai Lab's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zai Lab's regulatory disclosures and financial reporting.
Zai Lab Ltd (ZLAB) reported that its Chief Financial Officer, Chen Yajing, sold 260 American Depositary Shares (ADS) of the company on 2026-08-19 at $27.00 per ADS. Following this sale, Chen directly holds 35,635 ADS. Each ADS represents ten Ordinary Shares, and the ADSs and Ordinary Shares are described as fully fungible. The sale was effected under a Rule 10b5-1 trading plan adopted on December 9, 2025.
Zai Lab Ltd (ZLAB) is the issuer of American Depositary Shares that a former officer, Joshua L. Smiley, has notified for potential sale under Rule 144. The notice covers 98,653 American Depositary Shares, with an aggregate market value of $2,582,511.39, and an approximate sale date of August 20, 2026 through Fidelity Brokerage Services LLC on NASDAQ. The securities relate to a stock option exercise and are proposed to be sold for cash.
Zai Lab Ltd (ZLAB) has a shareholder, Chen Yajing, filing a notice of proposed sale of American Depositary Shares under Rule 144. The filing states that 260 ADS may be sold through Fidelity Brokerage Services LLC on or about 08/19/2026 on NASDAQ.
The 260 ADS were acquired from the issuer on 11/01/2025 through restricted stock vesting as compensation. The filing also lists prior sales by the same holder during the past three months, including 2,264 ADS on 06/26/2026 and 619 ADS on 08/11/2026, with corresponding aggregate sale values.
Zai Lab Ltd (ZLAB) reported an insider equity compensation event for its Chief Financial Officer, Yajing Chen. On 2026-08-14, 1,250 Restricted Share Units (RSUs) vested and were settled into 1,250 American Depositary Shares (ADSs), with each RSU delivering one ADS. Each ADS represents ten Ordinary Shares, and the company reports these holdings in ADS terms. On the same date, 427 ADSs were withheld at $25.90 per ADS to cover tax obligations arising from the vesting, leaving the remainder of the vested ADSs delivered to the reporting person. Following this vesting event, 1,250 RSUs remain outstanding and will continue to vest in equal annual installments over four years beginning on 2024-08-14, with vested shares delivered in ADS form.
Zai Lab Ltd director William Lis reported selling 8,506 American Depositary Shares (ADS) of the company on August 12, 2026 at $25.00 per ADS, in an open-market or private sale. The transaction was effected under a Rule 10b5-1 trading plan adopted on September 10, 2025. Following this sale, Lis directly holds 41,931 ADS, with each ADS representing ten ordinary shares.
Zai Lab Ltd Chief Financial Officer Chen Yajing sold 619 American Depositary Shares (ADS) on August 11, 2026 at $25.00 per ADS, leaving 35,072 ADS held directly. Each ADS represents ten Ordinary Shares. The sale was executed under a Rule 10b5-1 trading plan adopted on December 9, 2025.
William Lis filed to potentially sell 8,506 American Depositary Shares of Zai Lab Limited through Fidelity Brokerage Services on NASDAQ, with an indicated aggregate value of $212,650.00. The shares derive from restricted stock vesting that occurred on 06/29/2024 as compensation from the issuer.
In the past three months, a prior transaction shows 7,040 American Depositary Shares sold on 06/22/2026 for $127,353.60. The filing lists the security as American Depositary Shares with identifying code 430452680 and references a proposed sale date of 08/12/2026.
ZLAB filed a notice for a proposed sale of American Depositary Shares. The planned transaction covers 619 ADS, to be sold through Fidelity Brokerage Services LLC on 08/11/2026 on NASDAQ, with an aggregate value of 15,475.00. The seller, Yajing Chen, previously sold 2,264 ADS on 06/26/2026 for 39,532.38. The 619 ADS to be sold were originally acquired from restricted stock vesting on 10/01/2024 as compensation from the issuer.
Zai Lab reported second-quarter 2026 total revenues of $106.3 million, down modestly from the prior year, with net product revenue of $105.8 million. The company posted a net loss of $50.8 million, or $0.05 per ordinary share, as higher research and development spending offset revenue.
ZEJULA revenue declined as hospital utilization shifted following volume-based procurement for generic olaparib and VYVGART faced pricing adjustments tied to NRDL renewal, while XACDURO and NUZYRA delivered growth. Research and development expenses rose to $61.8 million, driven by increased upfront and milestone licensing fees.
Pipeline and regulatory progress was significant: Zai Lab launched KarXT for schizophrenia in mainland China and secured China approval for TIVDAK in recurrent or metastatic cervical cancer. Zoci (DLL3-targeting ADC) showed notable response rates in SCLC and extrapulmonary NECs and received FDA Fast Track and U.S./EU orphan designations. Cash, current restricted cash, and short-term investments totaled $717.5 million at June 30, 2026, which management expects to fund operations for at least the next 12 months.
Zai Lab Limited reported second quarter 2026 total revenue of $106.3 million, with net product revenue of $105.8 million and an 11% sequential increase versus the prior quarter. Research and development expenses rose to $61.8 million and selling, general and administrative expenses were $72.9 million. Loss from operations was $76.5 million, or $60.4 million on a non-GAAP basis excluding depreciation, amortization, and share-based compensation. Net loss was $50.8 million, or $0.05 per ordinary share and $0.46 per ADS. Cash, cash equivalents, short-term investments, and current restricted cash totaled $717.5 million as of June 30, 2026.
The company highlighted continued progress in its pipeline. Zocilurtatug pelitecan (zoci) received U.S. and EU orphan drug designations and a second FDA Fast Track Designation and is moving toward multiple registrational studies in small cell lung cancer and extrapulmonary neuroendocrine carcinomas. China’s NMPA approved TIVDAK for recurrent or metastatic cervical cancer, KarXT was commercially launched in mainland China for schizophrenia, and VYVGART’s U.S. label was expanded to all generalized myasthenia gravis serotypes. A BLA for povetacicept in IgA nephropathy was accepted with a PDUFA target action date of November 30, 2026, and management outlined several key data readouts and regulatory milestones expected through the first half of 2027.